Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06431607 · ClinicalTrials.gov registry record · Phase 2

A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults

A Phase 2 study, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 2
Development phase
845
Enrollment target

NCT06431607: Completed Phase 2 study, sponsored by GlaxoSmithKline.

NCT06431607 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 845 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (535% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06431607, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 2
Development phase
845 participants
Enrollment target

Study Summary

The purpose of this study is to assess the safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent vaccine (GSK4382276A) candidate against influenza, administered in healthy younger adults (YA) and older adults (OA).

Primary Outcome

Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus.

Interventions

  • BIOLOGICAL F2G22B/DL001Z
  • BIOLOGICAL F2H23D/DL001Z-NH
  • BIOLOGICAL F2H23B/DL001Z-NH
  • BIOLOGICAL F2H23H/DL001Z
  • COMBINATION_PRODUCT FDQ23A-NH (Flu D-QIV)

Trial Details

FieldValue
Enrollment Target 845 participants
Start Date 2024-05-23
Est. Completion 2025-06-04
Phase Phase 2
GlaxoSmithKline

1,345 total trials

What the finished NCT06431607 record still lists

NCT06431607 is an interventional study that assigns participants to a tested intervention. The registered 845 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (535% higher).

The record links to 0 conditions, and to 5 interventions - of which F2G22B/DL001Z is the first listed.

NCT06431607 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06431607 about?

NCT06431607 is a clinical study titled "A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults". The purpose of this study is to assess the safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent vaccine (GSK4382276A) candidate against influenza, administered in healthy younger adults (YA) and older adults (OA).

What is the current status of trial NCT06431607?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 845 participants. The study started on 2024-05-23. Estimated completion is 2025-06-04.

What interventions are being tested in trial NCT06431607?

The interventions under investigation include: F2G22B/DL001Z (BIOLOGICAL), F2H23D/DL001Z-NH (BIOLOGICAL), F2H23B/DL001Z-NH (BIOLOGICAL), F2H23H/DL001Z (BIOLOGICAL), FDQ23A-NH (Flu D-QIV) (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT06431607?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06431607's enrollment target sits among peer trials

845 36th of 2000 higher than 1,965 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02757859 · 845 participants · NA

    High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery

  • NCT06747949 · 844 participants · Phase 3

    A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

  • NCT06439979 · 843 participants · NA

    Rural Adult and Youth Sun Protection Study

  • NCT07142408 · 848 participants · Phase 3

    The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06431607, the US trial registry maintained by the National Library of Medicine. NCT06431607 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.